Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.60 |
| ▸ | RXRB | P28702 | 1/20 | 0.60 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.55 |
| ▸ | MARS1 | P56192 | 2/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.52 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6254589 | 0.90 | RXRA (0.59) | SRD5A2RXRARXRBPTGER1KMO | |
| SCHEMBL1513336 | 0.84 | BCL2L1 (0.49) | SRD5A2RXRARXRBPTGER1MARS1 | |
| SCHEMBL8779218 | 0.84 | SRD5A2 (0.68) | SRD5A2MARS1NPC1RAB9A | |
| SCHEMBL4682686 | 0.84 | AKR1C3 (0.62) | SRD5A2RXRARXRBPTGER1MRGPRX4 | |
| SCHEMBL3208003 | 0.83 | KMO (0.62) | SRD5A2RXRARXRBMARS1KMO | |
| SCHEMBL2371293 | 0.83 | KMO (0.61) | RXRARXRBPTGER1KMOCYP2C9 | |
| SCHEMBL2406313 | 0.82 | RXRA (0.58) | RXRARXRBPTGER1KMOCYP2C9 | |
| SCHEMBL12171448 | 0.82 | NPC1 (0.68) | SRD5A2RXRARXRBMRGPRX4CYP2C9 | |
| SCHEMBL444367 | 0.81 | SRD5A2 (0.90) | SRD5A2RXRARXRBMARS1MRGPRX4 | |
| SCHEMBL16574048 | 0.81 | RXRA (0.57) | RXRARXRBPTGER1MRGPRX4KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325651-B1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120309835-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | REVISION THERAPEUTICS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120288568-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | REVISION THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120202885-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | REVISION THERAPEUTICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8168663-B2 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1988397-B1 | COMPOSITIONS AND USES FOR STABILISING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2325651-A2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| WO-2007021991-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | SYTERA, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2007008821-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | SIRION THERAPEUTICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | SYTERA, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | disclosed |
| EP-1587821-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | The Scripps Research Institute (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040152140-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE | 2004-08-05 | — | — | US | disclosed |
| WO-2004056315-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288568-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | RBP1, RBP4, ALDH1A2 | SRD5A2 2047/4885RXRA 23/4885RXRB 13/4885 |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | SRD5A2 2969/4885RXRA 3616/4885RXRB 3630/4885 |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | SRD5A2 2969/4885RXRA 3616/4885RXRB 3630/4885 |
| US-20120309835-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, TTR | SRD5A2 1436/4885RXRA 51/4885RXRB 41/4885 |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | RBP1, RBP4, TTR | SRD5A2 1436/4885RXRA 51/4885RXRB 41/4885 |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | MC4R, MC5R, MC1R | SRD5A2 3187/4885RXRA 223/4885RXRB 160/4885 |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | RBP1, RBP4, ALDH1A2 | SRD5A2 2047/4885RXRA 23/4885RXRB 13/4885 |
| US-20120202885-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, TTR | SRD5A2 1436/4885RXRA 51/4885RXRB 41/4885 |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, TTPA, PRNP | SRD5A2 3150/4885RXRA 3902/4885RXRB 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.